GBT
TEVA icon

Grove Bank & Trust’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Grove Bank & Trust’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-100
Closed -$3.39K – 953
2026
Q2 		$3.39K Sell
100
-400
-80% -$13.3K ﹤0.01% 766
2026
Q1 		$15.1K Sell
500
-500
-50% -$16.1K ﹤0.01% 574
2025
Q4 		$31.2K Buy
1,000
+750
+300% +$18.5K ﹤0.01% 485
2025
Q3 		$5.05K Buy
+250
New +$4.39K ﹤0.01% 704
2017
Q3 		– Sell
-1,540
Closed -$51K – 655
2017
Q2 		$51K Buy
1,540
+1,090
+242% +$33.7K 0.03% 252
2017
Q1 		$14K Buy
450
+288
+178% +$9.83K 0.01% 322
2016
Q4 		$6K Hold
162
– – ﹤0.01% 443
2016
Q3 		$7K Hold
162
– – 0.01% 226
2016
Q2 		$8K Hold
162
– – 0.01% 216
2016
Q1 		$9K Hold
162
– – 0.01% 228
2015
Q4 		$11K Buy
+162
New +$10K 0.01% 268

Other funds holding TEVA

WWM
Whalen Wealth Management Las Vegas, Nevada $234M AUM 28.06% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
CAM
Cacti Asset Management Atlanta, Georgia $1.89B AUM 58.55% 1-Year Est. Return
IRC
Investors Research Corp Atlanta, Georgia $569M AUM 15.41% 1-Year Est. Return
VEM
Vann Equity Management Plano, Texas $168M AUM
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return
BAM
Byrne Asset Management Kingston, New Jersey $179M AUM 29.67% 1-Year Est. Return
EWP
Elevation Wealth Partners Santa Rosa, California $356M AUM 17.04% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.66B AUM 13.15% 1-Year Est. Return

Grove Bank & Trust's TEVA Position: Q3 2026 in Review

Grove Bank & Trust sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q3 2026, closing a stake of 100 shares — an estimated $3.39K sold.

Grove Bank & Trust first reported a position in TEVA in Q4 2015 and held it in 11 quarters. The position peaked at $51K in Q2 2017. 10 funds tracked by Wall St. Rank hold TEVA as of Q3 2026.

  • Grove Bank & Trust reported no remaining Teva Pharmaceutical Industries Limited position as of Q3 2026 after selling out during the quarter.
  • Grove Bank & Trust sold 100 Teva Pharmaceutical Industries Limited shares in Q3 2026, an estimated $3.39K.
  • Grove Bank & Trust first reported a position in Teva Pharmaceutical Industries Limited in Q4 2015 and held it in 11 quarters.
  • Grove Bank & Trust's Teva Pharmaceutical Industries Limited position peaked at $51K in Q2 2017.
  • 10 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q3 2026.

Based on Grove Bank & Trust's 13F filing for Q3 2026, filed 8 Oct 2026.